Skip to main content
GENINCODE PLC logo

GENINCODE PLC — Investor Relations & Filings

Ticker · GENI ISIN · GB00BL97B504 LEI · 213800UX6TE7K65O2892 IL Professional, scientific and technical activities
Open in API
Filings indexed 111 across all filing types
Latest filing 2023-12-21 Capital/Financing Update
Country GB United Kingdom
Listing IL GENI

About GENINCODE PLC

https://genincode.com/

GENINCODE PLC specializes in the genetic risk assessment and prediction of cardiovascular disease (CVD). The company develops and commercializes clinical genetic tests that combine genomic data with clinical algorithms and artificial intelligence (AI). These advanced risk assessment tools provide physicians with a predictive analysis of a patient's health, enabling personalized prevention and treatment strategies for CVD. The company's technology is founded on over 15 years of research and development in cardiovascular genomics, aiming to improve patient outcomes by identifying at-risk individuals before the onset of disease.

Recent filings

Filing Released Lang Actions
Placing and Subscription
Capital/Financing Update Classification · 1% confidence The document is an official announcement released via RNS (RNS Number : 6814X) on December 21, 2023. The content explicitly details a 'Placing and Subscription to raise a minimum of £4.0 million' and a 'Retail Offer to raise up to £1.0 million' involving the issuance of new ordinary shares. This clearly falls under corporate financing activities. The document also mentions a 'Notice of General Meeting' required to approve these actions. Since the primary focus is the fundraising through the issuance of new shares, the most specific category is Capital/Financing Update (CAP). Although it is distributed via RNS, CAP is more precise than the general fallback (RNS). The document is substantial and details the transaction, not just announcing that a report is available (which would suggest RPA or RNS).
2023-12-21 English
CARDIO inCode-Score 510(k) FDA submission update
Regulatory Filings Classification · 1% confidence The document is identified by the RNS Number header and the closing statement referencing RNS, the news service of the London Stock Exchange, which is approved by the FCA. The content announces a significant operational and regulatory update: GENinCode is transitioning its FDA submission for the CARDIO inCode-Score device from a 510(k) pathway to a De Novo pathway. This is a material corporate announcement regarding regulatory strategy and product commercialization, not a full financial report (like 10-K or IR), a transcript (CT), or a dividend notice (DIV). Since it is a formal, material announcement disseminated via the RNS system that doesn't fit perfectly into specific categories like M&A (TAR) or Director's Dealing (DIRS), the most appropriate classification is the general regulatory announcement category, RNS, as it is explicitly distributed through that service and contains material, non-financial news.
2023-11-29 English
Change of Adviser
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 9689U' and concludes with standard boilerplate text referencing 'RNS, the news service of the London Stock Exchange' and the FCA. The core content announces a 'Change of Adviser' (appointment of Cavendish Capital Markets Limited as Nominated Adviser and Broker). This type of announcement, which is a material corporate event disseminated via the Regulatory News Service (RNS), fits best under the general 'Regulatory Filings' category, as there is no specific category for 'Change of Adviser' or 'Appointment of Broker' among the provided options, and it is not a financial report, earnings release, or management change (MANG). Since it is a direct regulatory announcement distributed via RNS, RNS is the most appropriate classification.
2023-11-29 English
ShareSoc investor presentation
Regulatory Filings Classification · 1% confidence The document is a regulatory announcement (indicated by 'RNS Number') from GENinCode Plc. The core content announces that the CEO will provide a 'live presentation to investors at the ShareSoc & Walbrook PR Healthcare Companies Hybrid Event'. This is an announcement about the company's participation in an investor event, not the presentation material itself, nor is it a formal financial report (like 10-K or IR). Since it is an announcement regarding an upcoming investor engagement, it aligns best with the Investor Presentation (IP) category if the content were the presentation, but because it is merely an announcement of the event where a presentation will occur, and it is distributed via RNS, it fits the description of an Investor Presentation (IP) announcement or potentially a general Regulatory Filing (RNS). Given the specific mention of an 'investor presentation' event, 'IP' is a strong candidate, but the definition for 'IP' is 'Detailed presentation for investors'. Since this is an announcement *about* a presentation, and it is a general regulatory news service release, 'RNS' (Regulatory Filings - general fallback) is often used for such logistical announcements. However, the content explicitly mentions an 'investor presentation' event. Let's re-evaluate the definitions. 'IP' is the presentation itself. 'RPA' is the announcement of a report publication. This is an announcement of an *event* where a presentation will happen. Given the context of investor relations communication distributed via RNS, and the focus on an investor event, 'IP' (Investor Presentation) is the most contextually relevant classification for the *topic*, even if it's an announcement rather than the presentation itself, as it signals future investor engagement. However, following the 'MENU VS MEAL' rule strictly, if this were the presentation, it would be IP. Since it's an announcement of an event where a presentation will occur, and it's a general RNS release, 'RNS' is the safest fallback for an announcement that doesn't fit the specific report types. Let's check 'IP' again: 'Investor Presentation (Code: IP) Description: Detailed presentation for investors focusing on financials, strategy, and market position.' This document is *not* the presentation. It is an announcement about the event. Therefore, it is best classified as a general Regulatory Filing (RNS) or potentially a Report Publication Announcement (RPA) if we stretch the definition of 'report' to include investor presentations. Given it's a standard RNS release announcing an event, RNS is the most appropriate general classification.
2023-10-12 English
Half-year Report
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Interim report' and explicitly states it covers the 'six months ended 30 June 2023'. It contains detailed financial highlights, an operational review, a Chief Executive's statement, and a financial review section with specific revenue, gross profit, and EBITDA figures. This meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2023
2023-09-20 English
Notice of Results
Report Publication Announcement Classification · 1% confidence The document is a formal announcement disseminated via RNS (RNS Number : 2091M) from GENinCode Plc. The core content is a 'Notice of results,' specifically stating that the company 'will release its unaudited interim results for the six months ended 30 June 2023 on Wednesday, 20 September 2023.' It also mentions an accompanying investor presentation. Since the document itself is an announcement about the future release of the interim results (which would be an 'IR' filing), and it is being published through the regulatory news service (RNS), it fits the definition of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given the specific nature of announcing the publication date of a report, RPA is more precise than the general RNS fallback. However, the document is primarily a regulatory news service announcement (RNS) detailing an upcoming event and report release, and it is very short relative to the actual interim report it describes. Since it is a general regulatory announcement published via RNS, and RPA is for announcing the *publication* of a report (which this is, announcing the date), RPA is the best fit, as it signals the upcoming release of the Interim Report (IR).
2023-09-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.